Angiocept (pegdinetanib) / BMS - LARVOL DELTA

Mutational and biophysical robustness in a pre-stabilized monobody. (PubMed, J Biol Chem) - "In order to mitigate these losses, we grafted the binding loops from Adnectin-anti-VEGFR2 (CT-322) onto the pre-stabilized FN3Con scaffold to produce a domain that successfully bound with high affinity to the therapeutic target VEGFR2...Further investigations into buffer excipients doubled the presence of monomeric monobody in accelerated stability trials. These data suggest that loop grafting onto a pre-stabilized scaffold is a viable strategy for the development of monobody domains with desirable biophysical characteristics, and is therefore well-suited to applications such as the evolution of multiple paratopes or shelf-stable diagnostics and therapeutics."

Journal • FN1

Ph II trial of a novel anti-angiogenic agent in combination with chemotherapy for the second-line treatment of metastatic colorectal cancer (clinicaltrials.gov) - P2, N=17; N=116 -> 17; Active, not recruiting -> Completed

Enrollment • Trial completion • Colorectal Cancer • Oncology